Tuesday December 23, 2014 0 comments
DENVER - The Colorado BioScience Association (CBSA) reports the state attained a number of key financings, acquisitions and expansions in its bioscience industry in 2014.
"We've seen a number of exciting deals come to fruition in our Colorado bioscience community during 2014, which strengthens our state's position as a national industry leader," said April Giles, CBSA president and CEO.
Highlights of the year, according to CBSA, included:
- Terumo BCT breaking ground on a 120,000-square-foot global headquarters in Lakewood in April
- BioScience Park Center 2 breaking ground on a 112,000-square-foot addition in April
- Spectranetics acquiring California-based AngioScore Inc. for $230 million in June
- Covidien being acquired by Medtronic for $42.9 billion in June
- Clovis Oncology offering $200 million in convertible senior notes in a private placement to investors in September
- InDevR winning a $14.7 million BARDA contract for as cutting-edge influenza diagnostic in September
- SomaLogic announcing the extension its research agreement with Novartis in October
- N30 Pharmaceuticals securing $30 million in oversubscribed crossover financing in November
"We're thrilled that CBSA has continued to play a significant role in promoting Colorado as a dynamic region for bioscience innovation and investment," Giles said.